Client News

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Formycon Receives EU Approval for FYB203 (Aflibercept), a Biosimilar to Eylea®, Under the Brand Names AHZANTIVE® and Baiama®

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Formycon and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi® (Ustekinumab), a Biosimilar to Stelara®

Heidelberg Pharma AG Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma

Teva Becomes Strategic Commercialization Partner for Formycon’s Biosimilar Candidate FYB203 (Eylea® / aflibercept) in Major Parts of Europe and Israel

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Formycon Included in TecDAX Index of Deutsche Börse

BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

Newron and Myung In Pharm Announce License Agreement for Evenamide in South Korea